Precision Therapies for Musculoskeletal Health

First-in-class, versatile platform for localized, controlled and sustained
management and treatment of musculoskeletal conditions, in surgical and
non-surgical settings

About SIENI

SIENI is a pioneering biotech company, developing localized therapies to treat inflammation, infection, pain, and prevention of post-surgical complications of musculoskeletal diseases.. Our AEGEAL platform provides sustained and controlled delivery of FDA approved drugs frequently used in treatment of musculoskeletal diseases. Local delivery minimizes systemic exposure — enabling faster healing, safer recovery, and broader applicability across medical disciplines.

The AEGEAL Platform

Versatile. Bioresponsive. Precise.

Injectable gel delivery platform, developed with validated nanotechnology


Enables localized, sustained drug delivery, directly to injured tissue, at the site of trauma, surgical intervention or treatment

Rapid onset and minimal systemic effects

Adaptable across orthopedic, trauma, burn, and other applications

Potential for both human and veterinary use

AEGEAL Platform Technology

Potential to Advance Precision Therapies for Several Disease Areas

Sustained and programmable release 3-14 day delivery

Single dose – single administration improves compliance and avoids multiple interventions

Multimodal action loaded with 1+ APIs of proven efficacy

Local administration to affected tissue decreased systemic exposure

Higher tolerability and improved safety profile

The AEGEAL Platform

Versatile. Bioresponsive. Precise.

AEGEAL Platform Technology

Potential to Advance Precision Therapies for Several Disease Areas

Applications & Impact

Designed for Complex Challenges

“AEGEAL is for every knee and hip replacement surgery.”

 — OS, NYU Langone Orthopedics

Market Opportunity

33%

of the world suffers from
musculoskeletal conditions

$200B

annual cost in the U.S.
healthcare system

Growth

Significant growth driven by
aging population, trauma,
and competitive sports

$1B

Existing biologics set >$1B
revenue precedents

Leadership Team & Contact

Advisory Team

Fractional CCO/CBO

Lorem Ipsum Lorem